Impact of (Neo)Adjuvant Therapy Associating Anthracyclines and Taxanes With or Without Trastuzumab on Skeletal Muscle in Breast Cancer Patients (PROTECT-03)

Institut de cancérologie Strasbourg Europe

Status

Completed

Conditions

Breast Cancer

Treatments

Other: Microbiopsy sample

Other: Muscle echography, Maximal strength, Body composition, Quality of life and Physical activity level

Study type

Interventional

Funder types

Other

Identifiers

2020-A01266-33 (Other Identifier)

2020-006

Details and patient eligibility

About

This is an interventional, prospective and monocentric study. This study includes the evaluation before and after (neo)adjuvant therapy of :

Enrollment

13 patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

For group 1 without trastuzumab :

Patients must be ≥ 18 years old
Patients with breast cancer stage I to III
Patients who will receive (neo)adjuvant anthracyclines and weekly taxane, without trastuzumab
Patients must have a social security coverage
Patients able to speak, read and understand French

For group 2 with trastuzumab :

Patients must be ≥ 18 years old
Patients with breast cancer grade I to III
Patients who will receive (neo)adjuvant anthracyclines and weekly taxane, with trastuzumab
Patients must have a social security coverage
Patients able to speak, read and understand French

Exclusion criteria

History of cancer
Previous chemotherapy
Patients with known chronic pathology (musculoskeletal disorders, autoimmune, vascular or neuromuscular disease)
Pacemaker implantation
Contraindication to physical condition evaluation
Contraindication to local anesthesia required for microbiopsy
Patients < 18 years old or patients ≥ 18 years old under guardianship, or supervision
Psychiatric, musculoskeletal or neurologic disorders
Women that are pregnant or breast-feeding